Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
Michael A. Brodney(Vertex Pharmaceuticals (United States)), Brian T. O’Neill(Pfizer (United States)), Cathleen Gonzales, Aijia Yu(WuXi AppTec (China)), David Riddell(Eli Lilly (United States)), Kevin Parris, Erik LaChapelle(Pfizer (United States)), Luis Martinez-Alsina(Pfizer (United States)), Jayvardhan Pandit(Pfizer (United States)), Leanne M. Buzon(Pfizer (United States)), Kevin Ogilvie(Pfizer (United States)), Loren Price(Pfizer (United States)), Xinjun Hou(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Kevin E. Henegar(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), John C. Murray(Pfizer (United States)), Ashley Robshaw(Pfizer (United States)), Peter Mikochik(Pfizer (United States)), Mark W. Bundesmann(Pfizer (United States)), Subas M. Sakya(Pfizer (United States)), Yong Zhang(Princeton University), Christopher R. Butler(Pfizer (United States)), Ricardo Lira(Pfizer (United States)), Eric F. Johnson(Scripps Research Institute), Elizabeth M. Beck(Pfizer (United States)), Ying Fan(Scripps Research Institute), Jason K. Dutra(Pfizer (United States)), Bruce N. Rogers(Pfizer (United States)), Gabriela Barreiro(Pfizer (United States))
Cited by 78
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Decarboxylative alkylation for site-selective bioconjugation of native proteins via oxidation potentials
|Nature Chemistry|2017|378
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351